Trials / Completed
CompletedNCT05060471
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Locally Advanced Anal Canal Squamous Carcinoma Patients will be enrolled and given four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab. Treatment outcomes and toxicities will be evaluated.
Conditions
- Anal Canal Cancer
- Anal Squamous Cell Carcinoma
- Anal Cancer
- Anal Canal Cancer Stage I
- Anal Canal Cancer Stage II
- Anal Canal Cancer Stage III
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab | Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab. |
Timeline
- Start date
- 2021-10-27
- Primary completion
- 2024-06-21
- Completion
- 2024-11-27
- First posted
- 2021-09-29
- Last updated
- 2024-12-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05060471. Inclusion in this directory is not an endorsement.